Physician profile
Muhammad Rafiq
NPI 1639337835
$3,199.90
in general payments reported to CMS, 2019-2025
22 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $342 · 2021: $323 · 2022: $348 · 2023: $702 · 2024: $740 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Education: $33.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.07 |
| Education | $33.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $368.62 | 2020-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $357.04 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $356.59 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $281.34 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $279.37 | 2019-2025 | Farxiga |
| Amgen INC. | $271.48 | 2021-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $198.08 | 2023-2025 | |
| Epsfl, LLC | $189.81 | 2023 | |
| Calliditas Therapeutics US INC. | $179.44 | 2022-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $158.87 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.16 | 2022-2025 | |
| Ardelyx, INC. | $79.19 | 2023-2024 | Ibsrela |
| Aurinia Pharma U.S., INC. | $77.54 | 2022-2023 | Lupkynis |
| Glaxosmithkline, LLC. | $69.52 | 2021-2024 | Jesduvroq |
| Ani Pharmaceuticals, INC. | $65.41 | 2022-2025 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $60.62 | 2020-2024 | Veltassa |
| Cormedix INC. | $31.87 | 2024 | Defencath |
| Alnylam Pharmaceuticals INC. | $27.55 | 2023 | Onpattro |
| Siemens Medical Solutions USA, INC. | $20.41 | 2022 | |
| Akebia Therapeutics INC | $15.25 | 2019 | |
| Vantive US Healthcare LLC | $15.11 | 2025 | Renal - Pd |
| Biomerieux INC | $9.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Rafiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.